Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic gene therapy for cardiovascular disease.

K P Ponder1

  • 1Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Trends in Cardiovascular Medicine
|January 20, 2000
PubMed
Summary

Gene therapy shows promise for cardiovascular diseases like hypertension and hypercholesterolemia by transferring therapeutic genes. Further research is needed to improve long-term gene expression and regulation for human clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI.

Journal of inherited metabolic disease·2008
Same author

Walk a mile in the moccasins of people with haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same author

High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.

Journal of thrombosis and haemostasis : JTH·2007
Same author

Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA.

Haemophilia : the official journal of the World Federation of Hemophilia·2006
Same author

Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII.

Circulation·2004
Same author

Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver.

Hepatology (Baltimore, Md.)·2001

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cardiovascular Medicine

Background:

  • Systemic gene therapy aims to deliver genes into the body for therapeutic protein production.
  • Viral vectors like retroviral, adenovirus-associated, and adenoviral vectors are used, each with varying expression levels and durations.
  • Gene therapy has demonstrated potential in treating cardiovascular conditions through various delivery methods.

Purpose of the Study:

  • To review the potential of gene therapy in treating cardiovascular diseases.
  • To highlight successes and limitations of current gene therapy approaches.
  • To identify areas for future development in gene therapy for cardiovascular applications.

Main Methods:

  • Review of studies utilizing different viral vectors for gene transfer.

Related Experiment Videos

  • Analysis of gene therapy applications targeting specific cardiovascular conditions.
  • Evaluation of achieved protein levels and therapeutic effects in preclinical models.

    • Main Results:

    • Hepatic gene therapy achieved protective levels of protein C and tissue plasminogen activator.
    • Transient amelioration of hypercholesterolemia and hypertension was observed.
    • Fasting hyperglycemia was improved in diabetes models via insulin gene transfer.

    Conclusions:

    • Gene therapy holds significant potential for treating cardiovascular diseases.
    • Improvements in long-term gene expression and physiological regulation are crucial for clinical translation.
    • Further advancements are necessary before widespread human application for most cardiovascular disorders.